Combination Of Fulvestrant And Chemotherapy In Esr1 Y537s Mutant Breast Cancer Cells And Potential Synergy Mechanism Related To P53 Wildtype.

Wen Ma,Francisco Hermida-Prado,Cristina Guarducci,Avery Feit,Agostina Nardone, Gabriella Cohen,Wenting Pan,Hongliang Wei,Nanlin Li,Myles Brown,Rinath Jeseslsohn

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览25

暂无评分

摘要

1065Background: The acquisition of ligand-independent ESR1 mutations during endocrine therapy in metastatic ER+ breast cancer is a common mechanism of resistance to endocrine treatment, particularl...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要